GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » ROE % Adjusted to Book Value

Aldeyra Therapeutics (FRA:137) ROE % Adjusted to Book Value : -19.81% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aldeyra Therapeutics ROE % Adjusted to Book Value?

Aldeyra Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -83.60%. Aldeyra Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 4.22. Aldeyra Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -19.81%.

Aldeyra Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Aldeyra Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics ROE % Adjusted to Book Value Chart

Aldeyra Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.12 -39.53 -13.36 -15.77 -14.23

Aldeyra Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.95 -15.01 -31.21 -17.11 -19.81

Competitive Comparison of Aldeyra Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Aldeyra Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aldeyra Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's ROE % Adjusted to Book Value falls into.


;
;

Aldeyra Therapeutics ROE % Adjusted to Book Value Calculation

Aldeyra Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-60.04% / 4.22
=-14.23%

Aldeyra Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-83.60% / 4.22
=-19.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
EYPT TSHA RGNX STOK ALT SANA CELC RNAC ZVRA TRML VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ALDX:USA 137:Germany
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Website
https://www.aldeyra.com
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Aldeyra Therapeutics Headlines

No Headlines